Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Safety

Mifepristone

Overton Dodges Key Science Questions at Senate FDA Hearing

Her pledge to make the FDA’s mifepristone safety review an immediate priority comes as the agency must report to a court on Oct. 7.

Overton Sidesteps Questions at Senate FDA Confirmation Hearing

FDA Launches Retrospective Safety Study of Mifepristone

Judge Pauses Louisiana Challenge, Leaves Mail-Order Abortion Pill Policy Intact

GOP Senators Press FDA on Illegal Online Abortion Pill Sales, Launch Probe of Mifepristone Makers

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

Live Action Urges HHS and FDA to Suspend Mifepristone After Undercover Planned Parenthood Calls

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

FDA Opens Mifepristone Safety Review as 20 States Vow to Defend Access

FDA Commissioner Pledges Safety Review of Abortion Pill Mifepristone